Biogen, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Biogen, Inc. – Product Pipeline Review – 2016’, provides an overview of the Biogen, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Biogen, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Biogen, Inc.

The report provides overview of Biogen, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Biogen, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Biogen, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Biogen, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Biogen, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Biogen, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Biogen, Inc. Snapshot 7

Biogen, Inc. Overview 7

Key Information 7

Key Facts 7

Biogen, Inc. - Research and Development Overview 8

Key Therapeutic Areas 8

Biogen, Inc. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 16

Out-Licensed Products/Combination Treatment Modalities 17

Biogen, Inc. - Pipeline Products Glance 18

Biogen, Inc. - Late Stage Pipeline Products 18

Pre-Registration Products/Combination Treatment Modalities 18

Phase III Products/Combination Treatment Modalities 19

Biogen, Inc. - Clinical Stage Pipeline Products 20

Phase II Products/Combination Treatment Modalities 20

Phase I Products/Combination Treatment Modalities 21

Biogen, Inc. - Early Stage Pipeline Products 22

Preclinical Products/Combination Treatment Modalities 22

Discovery Products/Combination Treatment Modalities 23

Biogen, Inc. - Drug Profiles 24

coagulation factor IX (recombinant), Fc fusion protein 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

rituximab 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

aducanumab 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

amiselimod hydrochloride 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

BG-00011 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

natalizumab 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

opicinumab 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

raxatrigine hydrochloride 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

BG-00001 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

BIIB-054 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

BIIB-059 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

BIIB-061 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

BIIB-063 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

dapirolizumab pegol 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

5-D10 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

CNV-1061436 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

CNV-3000164 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

CNV-3000223 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Gene Therapy for Hemophilia B 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

NI-105 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

NI-205 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

PRT-2761 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Recombinant Protein to Replace Factor VIII for Hemophilia A 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecule to Antagonize GPR-84 for Chronic Pain 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecule to Inhibit mPGES-1 for Chronic Pain 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Small Molecules to Agonize ROR-Gamma for Autoimmune Disease 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Biogen, Inc. - Pipeline Analysis 63

Biogen, Inc. - Pipeline Products by Target 63

Biogen, Inc. - Pipeline Products by Route of Administration 66

Biogen, Inc. - Pipeline Products by Molecule Type 67

Biogen, Inc. - Pipeline Products by Mechanism of Action 68

Biogen, Inc. - Recent Pipeline Updates 70

Biogen, Inc. - Dormant Projects 83

Biogen, Inc. - Discontinued Pipeline Products 85

Discontinued Pipeline Product Profiles 85

baminercept alfa 85

BG-00010 85

BIIB-023 85

clenoliximab 85

CNF-1010 85

dexpramipexole dihydrochloride 86

naxifylline 86

Biogen, Inc. - Company Statement 87

Biogen, Inc. - Locations And Subsidiaries 88

Head Office 88

Other Locations & Subsidiaries 88

Biogen, Inc. - Key Manufacturing Facilities 92

Appendix 93

Methodology 93

Coverage 93

Secondary Research 93

Primary Research 93

Expert Panel Validation 93

Contact Us 93

Disclaimer 94

List of Tables

List of Tables

Biogen, Inc., Key Information 7

Biogen, Inc., Key Facts 7

Biogen, Inc. – Pipeline by Indication, 2016 9

Biogen, Inc. – Pipeline by Stage of Development, 2016 11

Biogen, Inc. – Monotherapy Products in Pipeline, 2016 12

Biogen, Inc. – Partnered Products in Pipeline, 2016 13

Biogen, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 14

Biogen, Inc. – Out-Licensed Products in Pipeline, 2016 16

Biogen, Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 17

Biogen, Inc. – Pre-Registration, 2016 18

Biogen, Inc. – Phase III, 2016 19

Biogen, Inc. – Phase II, 2016 20

Biogen, Inc. – Phase I, 2016 21

Biogen, Inc. – Preclinical, 2016 22

Biogen, Inc. – Discovery, 2016 23

Biogen, Inc. – Pipeline by Target, 2016 63

Biogen, Inc. – Pipeline by Route of Administration, 2016 66

Biogen, Inc. – Pipeline by Molecule Type, 2016 67

Biogen, Inc. – Pipeline Products by Mechanism of Action, 2016 68

Biogen, Inc. – Recent Pipeline Updates, 2016 70

Biogen, Inc. – Dormant Developmental Projects,2016 83

Biogen, Inc. – Discontinued Pipeline Products, 2016 85

Biogen, Inc., Other Locations 88

Biogen, Inc., Subsidiaries 88

Biogen, Inc., Key Manufacturing Facilities 92

List of Figures

List of Figures

Biogen, Inc. – Pipeline by Top 10 Indication, 2016 9

Biogen, Inc. – Pipeline by Stage of Development, 2016 11

Biogen, Inc. – Monotherapy Products in Pipeline, 2016 12

Biogen, Inc. – Partnered Products in Pipeline, 2016 13

Biogen, Inc. – Out-Licensed Products in Pipeline, 2016 16

Biogen, Inc. – Pipeline by Top 10 Target, 2016 63

Biogen, Inc. – Pipeline by Route of Administration, 2016 66

Biogen, Inc. – Pipeline by Molecule Type, 2016 67

Biogen, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 68

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports